Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FALMINA vs ALTAVERA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the synaptic cleft, leading to increased serotonin levels.
Combination of ethinyl estradiol and desogestrel: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; desogestrel (progestin) causes cervical mucus thickening and endometrial atrophy, preventing implantation.
Major depressive disorder,Obsessive-compulsive disorder,Panic disorder,Bulimia nervosa,Premenstrual dysphoric disorder
Prevention of pregnancy,Treatment of moderate acne vulgaris (in females ≥15 years with no contraindications)
FALMINA (fictitious drug): 500 mg orally every 12 hours.
1 tablet (ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg) orally once daily for 21 days, followed by 7 placebo days.
Terminal elimination half-life 12-15 hours; in severe renal impairment (Cr Cl <30 m L/min) extends to 30-40 hours, requiring dose adjustment.
Levonorgestrel: terminal elimination half-life 25±10 hours; ethinyl estradiol: 13±7 hours. Clinical context: steady-state concentrations achieved within 5-7 days; contraceptive efficacy requires consistent daily dosing.
Hepatic via CYP2D6; active metabolite norfluoxetine; elimination half-life 4-6 days (fluoxetine), 4-16 days (norfluoxetine).
Ethinyl estradiol: primarily metabolized by CYP3A4; undergoes sulfation and glucuronidation. Desogestrel: rapidly converted to active metabolite etonogestrel via CYP2C9 and CYP2C19; further metabolism by CYP3A4.
Primarily renal (85% unchanged drug, 10% as glucuronide conjugate); biliary/fecal 5%.
Renal excretion of metabolites and unchanged drug: ~30% (levonorgestrel) and ~20% (ethinyl estradiol) in urine; biliary/fecal elimination: ~40-50% as conjugates and metabolites.
98% bound to albumin.
Levonorgestrel: 98-99% bound to sex hormone-binding globulin (SHBG) and albumin; ethinyl estradiol: 98% bound to albumin.
0.2-0.3 L/kg, reflecting confinement to plasma and interstitial space; minimal tissue penetration.
Levonorgestrel: Vd ~1.8 L/kg (suggesting extensive tissue distribution). Ethinyl estradiol: Vd ~2.4 L/kg.
Oral: 75-85% due to moderate first-pass metabolism; IV: 100%.
Oral bioavailability: levonorgestrel ~100% (nearly complete); ethinyl estradiol ~45-50% (first-pass hepatic metabolism).
GFR 30-59 m L/min: 500 mg every 24 hours. GFR 15-29 m L/min: 250 mg every 24 hours. GFR <15 m L/min: 125 mg every 24 hours. Hemodialysis: 125 mg post-dialysis.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal disease or acute renal failure due to potential fluid retention.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50%. Child-Pugh Class C: use with caution; 250 mg every 24 hours.
Contraindicated in severe hepatic dysfunction (Child-Pugh class B or C). Use caution in mild to moderate impairment (Child-Pugh A); monitor liver enzymes.
5 mg/kg/dose orally every 12 hours; maximum 500 mg/dose.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults (1 tablet daily, 21/7 regimen) after evaluation of risks.
Initiate at 250 mg orally every 12 hours; titrate to renal function.
Not indicated for postmenopausal women. No specific geriatric dosing; consider increased risk of thromboembolism, cardiovascular disease, and metabolic effects in older women of reproductive age.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age (especially >35 years) and with number of cigarettes smoked. Women who use combined hormonal contraceptives should be strongly advised not to smoke.
Serotonin syndrome; discontinuation syndrome; hyponatremia; bleeding risk; mania/hypomania; seizures; angle-closure glaucoma; QT prolongation (overdose).
Thrombotic disorders: risk of venous thromboembolism (VTE), stroke, myocardial infarction; discontinue if thrombotic event occurs.,Hepatic disease: discontinue if jaundice or liver function abnormalities develop.,Hypertension: monitor blood pressure; discontinue if uncontrolled.,Carbohydrate metabolism: may affect glucose tolerance; monitor diabetic patients.,Depression: discontinue if significant depression occurs.,Gallbladder disease: increased risk of cholelithiasis.
Concurrent use with MAOIs or within 14 days of MAOI use; concurrent use with pimozide or thioridazine; hypersensitivity to fluoxetine.
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast carcinoma,Estrogen-dependent neoplasia (known or suspected),Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma (known or suspected),Pregnancy (known or suspected),Hypersensitivity to any component
Avoid high-sodium foods as they can counteract the diuretic effect. Limit licorice intake (glycyrrhizin) which can worsen hypokalemia. Grapefruit juice may increase absorption; avoid large amounts. Maintain adequate fluid intake unless fluid restriction is advised.
No significant food interactions. Alcohol does not affect efficacy but may increase risk of adverse effects such as nausea. Grapefruit juice has no known interaction. Avoid excessive alcohol consumption due to potential hepatotoxicity.
Falmina is a combined oral contraceptive containing ethinylestradiol and drospirenone. Category X: contraindicated in pregnancy. First trimester: no increased risk of major malformations in exposed fetuses based on epidemiological studies, but use is not recommended due to lack of need. Second and third trimesters: associated with increased risk of fetal harm including congenital anomalies (limb defects, heart defects) and adverse outcomes (low birth weight, preterm birth) from continued exposure. Risk of fetal feminization from progestin component in late pregnancy.
ALTAVERA contains ethinyl estradiol and levonorgestrel. First trimester: Inadvertent exposure during organogenesis is associated with a very low absolute risk of cardiovascular defects (relative risk 1.2-1.4) and no consistent increase in other major malformations. Second and third trimesters: No known teratogenic effects, but theoretical risks from estrogenic effects (e.g., feminization of male fetus). Postnatal: No increased risk of long-term developmental effects from pregnancy exposure.
Small amounts of ethinylestradiol and drospirenone are excreted in breast milk; M/P ratio not determined. Use may reduce milk production and composition. Avoid use in breastfeeding women, especially during early postpartum period, due to potential for decreased milk supply and presence in milk. Alternative contraception recommended.
Combined oral contraceptives may reduce milk production and quality, especially in early lactation. Ethinyl estradiol transfers into breast milk at low levels (M/P ratio approximately 0.1-0.2), excluding clinical effects in term infants. Levonorgestrel transfer is minimal (M/P ratio ~0.2-0.4). Use is generally avoided in breastfeeding women, especially during the first 6 weeks postpartum. Progestin-only methods are preferred.
Falmina is contraindicated in pregnancy; no dose adjustments are applicable because use should be discontinued immediately upon pregnancy diagnosis. No pharmacokinetic data guide dosing in pregnancy as it is not indicated.
Contraindicated in pregnancy. No dose adjustment recommended because use is discontinued upon confirmed or suspected pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased hepatic clearance, altered binding proteins) are not relevant for this indication.
FALMINA is a high-ceiling loop diuretic used for edema and hypertension. Monitor serum potassium and magnesium regularly; risk of hypokalemia and hypomagnesemia. Ototoxicity is dose-dependent and more common with rapid IV administration or concurrent use of other ototoxic drugs. Onset of action: oral 30-60 min, IV 5 min. Duration: oral 6-8 hr, IV 2 hr. Avoid in anuria, hepatic coma, severe electrolyte depletion.
ALTAVERA is a combined oral contraceptive (COC) containing ethinylestradiol and levonorgestrel. It inhibits ovulation via suppression of gonadotropins. Counsel patients to take at the same time daily to maintain efficacy. Missed pill management: if missed within 12 hours, take immediately; if >12 hours, take last missed pill and use backup contraception for 7 days. Be aware of increased VTE risk, especially in smokers over 35. May reduce effectiveness of lamotrigine; monitor seizure control. Initiate on the first day of menses or first Sunday after onset.
Take this medication exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Report any hearing loss, ringing in ears, or dizziness immediately, especially if on high doses or other ototoxic drugs.,Weigh yourself daily and notify your doctor if you gain more than 2-3 pounds in 24 hours or lose weight too quickly.,Avoid sudden position changes to prevent dizziness; rise slowly from sitting or lying down.,Limit alcohol intake as it may worsen dizziness and low blood pressure.,This drug may increase blood sugar; monitor glucose if diabetic.,Do not take with NSAIDs (e.g., ibuprofen, aspirin) unless approved by your doctor as they may reduce effectiveness and increase kidney risk.
Take one tablet daily at the same time each day, with or without food.,If you miss a pill by less than 12 hours, take it as soon as you remember. If more than 12 hours, take the missed pill and use a backup method (e.g., condoms) for the next 7 days.,Smoking increases your risk of serious cardiovascular side effects, especially if you are over 35 years old. Do not smoke while taking this medication.,Seek immediate medical attention if you experience sudden severe headache, chest pain, leg pain/swelling, or vision changes (symptoms of blood clots).,This medication does not protect against HIV or other sexually transmitted infections.,If you are taking lamotrigine or other anticonvulsants, tell your doctor; your seizure medication may be less effective.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FALMINA vs ALTAVERA, answered by our medical review team.
FALMINA is a Oral Contraceptive that works by Selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the synaptic cleft, leading to increased serotonin levels.. ALTAVERA is a Combined Oral Contraceptive that works by Combination of ethinyl estradiol and desogestrel: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; desogestrel (progestin) causes cervical mucus thickening and endometrial atrophy, preventing implantation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FALMINA and ALTAVERA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FALMINA is: FALMINA (fictitious drug): 500 mg orally every 12 hours.. The standard adult dose of ALTAVERA is: 1 tablet (ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg) orally once daily for 21 days, followed by 7 placebo days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FALMINA and ALTAVERA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FALMINA is classified as Category C. Falmina is a combined oral contraceptive containing ethinylestradiol and drospirenone. Category X: contraindicated in pregnancy. First trimester: no increased risk of major malform. ALTAVERA is classified as Category C. ALTAVERA contains ethinyl estradiol and levonorgestrel. First trimester: Inadvertent exposure during organogenesis is associated with a very low absolute risk of cardiovascular def. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.